XBP1 and B-cell non-Hodgkin lymphoma: Of note, we found that the 4μ8C/AZD2461 combination was effective also against PEL cells, another B-cell lymphoma known to be strongly dependent on UPR activation, particularly on the IRE1α/XBP1 axis [25].